The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
At least 18 years of age
At least 6 months of data prior to the index date
Left ventricular ejection fraction (LVEF) > 40 %
N-terminal Pro-B-type natriuretic peptide (NT-proBNP) > 125 pg/mL or brain natriuretic peptide (BNP) ≥ 35 pg/mL
None
Chines patients with a heart failure and preserved ejection fraction (HFpEF) diagnosis who initiate Jardiance® after 1st of March 2023
Cohort
Retrospective
Not listed
Incidence of the composite outcome of HHF (the first HHF after the index date) or CV death
HHF=Hospitalization for Heart Failure CV=cardiovascular
Incidence of CV death
Incidence of the HHF (the first HHF after the index date)
Occurrence of death from any cause
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
